ChromaDex (CDXC) Stock Forecast, Price & News

ChromaDex (NASDAQ:CDXC) Frequently Asked Questions

Is ChromaDex a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ChromaDex in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ChromaDex stock.
View analyst ratings for ChromaDex or view top-rated stocks.

Are investors shorting ChromaDex?

ChromaDex saw a increase in short interest in the month of April. As of April 30th, there was short interest totaling 3,440,000 shares, an increase of 27.4% from the April 15th total of 2,700,000 shares. Based on an average trading volume of 448,700 shares, the days-to-cover ratio is currently 7.7 days. Currently, 8.9% of the company's shares are sold short.
View ChromaDex's Short Interest.

When is ChromaDex's next earnings date?

ChromaDex is scheduled to release its next quarterly earnings announcement on Tuesday, August 2nd 2022.
View our earnings forecast for ChromaDex.

How were ChromaDex's earnings last quarter?

ChromaDex Co. (NASDAQ:CDXC) posted its quarterly earnings results on Thursday, May, 12th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by $0.02. ChromaDex had a negative net margin of 39.25% and a negative trailing twelve-month return on equity of 81.32%. During the same period last year, the business earned ($0.12) earnings per share.
View ChromaDex's earnings history.

What guidance has ChromaDex issued on next quarter's earnings?

ChromaDex issued an update on its FY 2022 earnings guidance on Thursday, May, 19th. The company provided EPS guidance of for the period. The company issued revenue guidance of $77.57 million-$80.94 million, compared to the consensus revenue estimate of $79.36 million.

What price target have analysts set for CDXC?

3 brokers have issued 1 year price objectives for ChromaDex's shares. Their forecasts range from $6.00 to $8.00. On average, they expect ChromaDex's share price to reach $7.00 in the next twelve months. This suggests a possible upside of 266.5% from the stock's current price.
View analysts' price targets for ChromaDex or view top-rated stocks among Wall Street analysts.

Who are ChromaDex's key executives?

ChromaDex's management team includes the following people:

• Mr. Frank Louis Jaksch Jr., Co-Founder & Exec. Chairman (Age 54, Pay $504.3k)
• Mr. Robert N. Fried, CEO & Director (Age 62, Pay $679.87k)
• Mr. Kevin M. Farr CPA, Chief Financial Officer (Age 64, Pay $410.62k)
• Mr. Ben Shichman, Chief Technical Officer
• Dr. Andrew Shao Ph.D., Sr. VP of Global Regulatory & Scientific Affairs
• Brianna Gerber, VP of Fin. & Investor Relations
• Alex Worsham, VP of Global Marketing & Communications
• Mr. Fadi Karam, Chief Marketing Officer
• David Kroes, Sr. VP of People Matters
• Ms. Chu Yan, Managing Director of Asia Pacific

What is Robert Fried's approval rating as ChromaDex's CEO?

10 employees have rated ChromaDex CEO Robert Fried on Glassdoor.com. Robert Fried has an approval rating of 38% among ChromaDex's employees. This puts Robert Fried in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of ChromaDex's key competitors?

Some companies that are related to ChromaDex include True Drinks (TRUU), Canopy Rivers (RIV), Haymaker Acquisition Corp. III (HYAC), Ayr Wellness (AYRWF), Mind Medicine (MindMed) (MNMD), Exactus (EXDI), MariMed (MRMD), HEXO (HEXO), Grove (GRVI), IM Cannabis (IMCC), Natural Alternatives International (NAII), MediWound (MDWD), FitLife Brands (FTLF), Mannatech (MTEX) and Bon Natural Life (BON).
View all of CDXC's competitors.

What other stocks do shareholders of ChromaDex own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ChromaDex investors own include Sorrento Therapeutics (SRNE), Heron Therapeutics (HRTX), ADMA Biologics (ADMA), Athersys (ATHX), Bionano Genomics (BNGO), Matinas BioPharma (MTNB), Tilray (TLRY), Dynavax Technologies (DVAX), Glu Mobile (GLUU) and Great Panther Mining (GPL).

What is ChromaDex's stock symbol?

ChromaDex trades on the NASDAQ under the ticker symbol "CDXC."

Who are ChromaDex's major shareholders?

ChromaDex's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Yong Rong HK Asset Management Ltd (5.96%), BlackRock Inc. (4.62%), Vanguard Group Inc. (4.07%), Tieton Capital Management LLC (2.09%), State Street Corp (1.36%) and Northern Trust Corp (0.63%). Company insiders that own ChromaDex stock include Frank L Jaksch Jr, Kevin M Farr, Robert N Fried and Stephen A Block.
View institutional ownership trends for ChromaDex.

Which institutional investors are selling ChromaDex stock?

CDXC stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Yong Rong HK Asset Management Ltd, BlackRock Inc., PDT Partners LLC, UBS Group AG, Northern Trust Corp, and Oppenheimer & Co. Inc..
View insider buying and selling activity for ChromaDex or view top insider-selling stocks.

Which institutional investors are buying ChromaDex stock?

CDXC stock was bought by a variety of institutional investors in the last quarter, including Tieton Capital Management LLC, Renaissance Technologies LLC, Vanguard Group Inc., GSA Capital Partners LLP, State Street Corp, Crestwood Advisors Group LLC, JPMorgan Chase & Co., and XTX Topco Ltd. Company insiders that have bought ChromaDex stock in the last two years include Kevin M Farr, and Robert N Fried.
View insider buying and selling activity for ChromaDex or or view top insider-buying stocks.

How do I buy shares of ChromaDex?

Shares of CDXC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ChromaDex's stock price today?

One share of CDXC stock can currently be purchased for approximately $1.91.

How much money does ChromaDex make?

ChromaDex has a market capitalization of $130.52 million and generates $67.45 million in revenue each year. The company earns $-27.13 million in net income (profit) each year or ($0.40) on an earnings per share basis.

How many employees does ChromaDex have?

ChromaDex employs 115 workers across the globe.

What is ChromaDex's official website?

The official website for ChromaDex is www.chromadex.com.

How can I contact ChromaDex?

ChromaDex's mailing address is 10900 Wilshire Blvd. Suite 650, Los Angeles CA, 90024. The company can be reached via phone at (310) 388-6706, via email at [email protected], or via fax at 949-419-0294.